SURPASS-CVOT was a cardiovascular outcomes trial comparing tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease.
Quick summary
The main patient-facing takeaway is careful: tirzepatide was shown to be noninferior to dulaglutide for major cardiovascular events in the trial population. That is not the same as saying it is automatically best for every person.
Key takeaways
- The trial studied people with type 2 diabetes and established cardiovascular disease.
- Dulaglutide was an active comparator with prior cardiovascular benefit evidence.
- Tirzepatide met the trial’s noninferiority goal for the primary cardiovascular outcome.
- Medicine choice still depends on glucose, weight, heart disease, kidney function, side effects, access, and patient preference.
Why the comparator matters
Many heart-outcome trials compare a medicine with placebo. SURPASS-CVOT compared tirzepatide with dulaglutide, a GLP-1 receptor agonist already known to have cardiovascular benefit. That makes the result clinically useful, but it also means the headline needs nuance.
A person without established cardiovascular disease, a person with type 1 diabetes, a pregnant person, or someone with severe gastrointestinal problems may not match the trial population.
What to ask
- Do I have established ASCVD or high-risk features?
- Is tirzepatide being chosen for glucose, weight, heart risk, or several reasons?
- How will side effects be managed?
- Will insulin or sulfonylurea doses need review to reduce low-blood-sugar risk?
- What does insurance cover?
Practical takeaway
SURPASS-CVOT strengthens the heart-safety conversation for tirzepatide, but individual prescribing still needs a full risk review.
Safety note
This article is not a substitute for medical care. Seek urgent care for chest pain, stroke symptoms, severe dehydration, severe abdominal pain, or symptoms that feel unsafe.
What to ask your care team
- Do I match the SURPASS-CVOT population?
- What heart, kidney, and glucose goals are we treating?
- What side effects should make me call?
Related reading
Source summary
- Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes, New England Journal of Medicine. Randomized clinical trial. Accessed June 5, 2026. Source
- Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes, PubMed. Clinical trial abstract. Accessed June 5, 2026. Source
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes 2026, American Diabetes Association. Clinical guideline. Accessed June 5, 2026. Source
- Drug Trials Snapshot: Mounjaro, U.S. Food and Drug Administration. Regulatory summary. Accessed June 5, 2026. Source